This week’s Obesity update highlights regulatory progress, portfolio expansion, leadership changes, generic competition strategies, and evolving patient access initiatives across global markets.
In this Newsletter
Dive deeper
🧬 Ascletis files ASC36 and ASC36_35 obesity INDs [1] [US • 06 Jul 2026]
https://www.prnewswire.com/apac/news-releases/ascletis-submits-two-ind-applications-to-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-amylin-receptor-agonist-and-asc3635-fdc-once-monthly-injection-a-co-formulation-of-asc36-plus-peptide-glp-1-302817980.html
Context: Ascletis Pharma submitted US FDA INDs for ASC36 and ASC36_35 FDC for obesity.
Key point: ASC36 is a peptide amylin receptor agonist; ASC36_35 combines ASC36 with ASC35, a GLP-1R/GIPR agonist.
Implication: Signals pipeline investment and modality expansion.
💊 Azurity acquires CONTRAVE and related assets [2] [30 Jun 2026]
https://azurity.com/azurity-pharmaceuticals-expands-portfolio-with-contrave-and-related-assets/
Context: CONTRAVE (naltrexone HCl / bupropion HCl) is an established oral chronic weight management medicine.
Key point: Azurity Pharmaceuticals acquired CONTRAVE and related assets to expand in obesity and chronic weight management.
Implication: Signals pipeline investment and modality expansion.
🧑🔬 Hanmi promotes obesity pipeline and global BD leaders [3] [Korea • 02 Jul 2026]
https://biz.chosun.com/en/en-science/2026/07/02/TGVEIHTK2JAFZPNF7JLF24R6KU/
Context: Hanmi Group promoted six executives across Hanmi Science and Hanmi Pharmaceutical.
Key point: Promotions include leaders linked to H.O.P (Hanmi Obesity Pipeline), LAPSCOVERY, and global technology export activity.
Implication: Signals pipeline investment and modality expansion.
🇰🇷 JETEMA advances Korea GLP-1 generic strategy [4] [Korea • 03 Jul 2026]
https://biz.chosun.com/en/en-science/2026/07/02/XCYHJL7EJNEOXIE2EDMC7DISDY/
Context: JETEMA plans to introduce and commercialize a semaglutide GLP-1 receptor agonist generic in Korea.
Key point: The company aims to begin MFDS approval work in 2026 and target a 2028 launch after domestic patent expiry.
Implication: Introduces competition that may affect pricing and formulary access.
🏥 Novo Nordisk opens Wegovy Medicare GLP-1 Bridge [5] [US • 01 Jul 2026]
https://www.prnewswire.com/news-releases/wegovy-is-now-accessible-to-eligible-medicare-beneficiaries-living-with-obesity-through-medicare-glp-1-bridge-302815200.html
Context: Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge for eligible Medicare beneficiaries with obesity.
Key point: The program offers access for a $50 monthly copay and runs through the end of 2027.
Implication: May expand screening, initiation, and follow-up at scale.
Why it matters
- Obesity pipelines are broadening beyond weekly GLP-1s into amylin, GLP-1R/GIPR, and long-acting depot formulations.
- Established products such as CONTRAVE remain commercially relevant as obesity care expands.
- Korea-linked companies are positioning around both branded innovation and future generic competition.
- Access programs remain a major commercial lever as Medicare obesity coverage constraints persist.
- Platform stories, including Ascletis’ ULAP and Hanmi’s LAPSCOVERY, are central to obesity BD narratives.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
📚 View the full Obesity archive on our research hub page
🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team.
FAQ
What did Ascletis submit to the US FDA?
Ascletis submitted two IND applications for ASC36 and ASC36_35 FDC in obesity. ASC36 targets the amylin receptor, while ASC36_35 combines ASC36 with ASC35, a GLP-1R/GIPR agonist. [1]
What is CONTRAVE, and why is Azurity buying it?
CONTRAVE is naltrexone HCl / bupropion HCl, an oral medicine for chronic weight management. Azurity said the acquisition expands its obesity and chronic weight management portfolio. [2]
What is Hanmi’s H.O.P project?
H.O.P stands for Hanmi Obesity Pipeline. The source describes it as Hanmi Pharmaceutical’s growth strategy for obesity and metabolic diseases. [3]
What is JETEMA planning with semaglutide in Korea?
JETEMA plans to introduce and commercialize a semaglutide GLP-1 generic in Korea, with a stated target launch in 2028 after domestic patent expiry. [4]
Who can access Wegovy through the Medicare GLP-1 Bridge?
The source says eligible Medicare beneficiaries living with obesity can access Wegovy through the program, with physician prescription and prior authorization steps. [5]
Entities / Keywords
Ascletis Pharma, Ascletis, ASC36, ASC36_35 FDC, ASC35, amylin receptor agonist, GLP-1R/GIPR agonist, ULAP, SALD
Azurity Pharmaceuticals, Azurity, CONTRAVE, Mysimba, naltrexone HCl / bupropion HCl, chronic weight management
Hanmi Group, Hanmi Science, Hanmi Pharmaceutical, H.O.P, Hanmi Obesity Pipeline, LAPSCOVERY
JETEMA, semaglutide generic, Wegovy, Ozempic, GLP-1 receptor agonist, MFDS, Korea ETC business
Novo Nordisk, Wegovy, semaglutide, Medicare GLP-1 Bridge, NovoCare, Medicare beneficiaries
References
- https://www.prnewswire.com/apac/news-releases/ascletis-submits-two-ind-applications-to-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-amylin-receptor-agonist-and-asc3635-fdc-once-monthly-injection-a-co-formulation-of-asc36-plus-peptide-glp-1-302817980.html
- https://azurity.com/azurity-pharmaceuticals-expands-portfolio-with-contrave-and-related-assets/
- https://biz.chosun.com/en/en-science/2026/07/02/TGVEIHTK2JAFZPNF7JLF24R6KU/
- https://biz.chosun.com/en/en-science/2026/07/02/XCYHJL7EJNEOXIE2EDMC7DISDY/
- https://www.prnewswire.com/news-releases/wegovy-is-now-accessible-to-eligible-medicare-beneficiaries-living-with-obesity-through-medicare-glp-1-bridge-302815200.html